Archives of Neuroscience

Published by: Kowsar

Evidence-Based Pharmacotherapy of Epilepsy

Zahra Tolou Ghamari 1 , * , Jafar Mehavari Habibabadi 2 and Abbas Ali Palizban 3
Authors Information
1 Isfahan Neurosciences Research Centre, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, IR Iran
2 Department of Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, IR Iran
3 Department of Clinical Biochemistry, Isfahan University of Medical Sciences, Isfahan, IR Iran
Article information
  • Archives of Neuroscience: January 01, 2015, 2 (1); e18468
  • Published Online: January 1, 2015
  • Article Type: Research Article
  • Received: February 24, 2014
  • Revised: March 2, 2014
  • Accepted: March 10, 2014
  • DOI: 10.5812/archneurosci.18468

To Cite: Tolou Ghamari Z, Mehavari Habibabadi J, Palizban A A. Evidence-Based Pharmacotherapy of Epilepsy, Arch Neurosci. 2015 ; 2(1):e18468. doi: 10.5812/archneurosci.18468.

Copyright © 2015, Tehran University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Chandra S, Kurwale N, Tripathi M, Banerjee J. Epileptogenic networks and drug-resistant epilepsy: Present and future perspectives of epilepsy research-Utility for the epileptologist and the epilepsy surgeon. Ann Indian Acad Neur. 2014; 17(5): 134[DOI]
  • 2. Kalviainen R, Ansakorpi H, Flander S, Immonen A, Keranen T, Kivisto J, et al. [Update on Current Care Guideline: epilepsies (adult]. Duodecim. 2014; 130(7): 748-9[PubMed]
  • 3. Franchi C, Giussani G, Messina P, Montesano M, Romi S, Nobili A. Validation of healthcare administrative data for the diagnosis of epilepsy. J Epidemiol Community Health. 2013; 67(12)[DOI]
  • 4. Wiebe S. Definition of drug-resistant epilepsy: Is it evidence based? Epilepsia. 2013; 54: 9-12[DOI]
  • 5. Weaver DF, Pohlmann-Eden B. Pharmacoresistant epilepsy: Unmet needs in solving the puzzle(s). Epilepsia. 2013; 54: 80-5[DOI]
  • 6. Hao X, Goldberg D, Kelly K, Stephen L, Kwan P, Brodie MJ. Uncontrolled epilepsy is not necessarily the same as drug-resistant epilepsy: differences between populations with newly diagnosed epilepsy and chronic epilepsy. Epilepsy Behav. 2013; 29(1): 4-6[DOI][PubMed]
  • 7. Gregory JK, Broomall EM. Teaching Video NeuroImages: Reading epilepsy: A seizure in a thousand words (or less). Neurology. 2013; 81(13)[DOI]
  • 8. Cecen GS, Gulabi D, Oltulu I, Onay T. Generalized epileptic seizure in an adolescent idiopathic scoliosis (AIS) patient with syringomyelia after deformity correction surgery. Int J Surg Case Rep. 2013; 4(8): 740-3[DOI]
  • 9. Lasoń W, Chlebicka M, Rejdak K. Research advances in basic mechanisms of seizures and antiepileptic drug action. Pharmacol Rep. 2013; 65(4): 787-801[DOI]
  • 10. Tolou Ghamari Z. Antiepileptic Drugs (AEDs) Polypharmacy could lead to buried pharmacokinetic interactions due to CYP450. Drug Metab Lett . 2012; 6(3): 207-12
  • 11. Tolou-Ghamari Z, Najafi MR, Habibabadi JM, Zare M. Preliminarily Analysis of Carbamazepine (CBZ) C0 in Patients Visited Isfahan Epileptic Clinics. Int J Prev Med. 2013; 4-6[PubMed]
  • 12. Tolou-Ghamari Z, Zare M, Habibabadi JM, Najafi MR. Antiepileptic drugs: a consideration of clinical and biochemical outcome in patients with epilepsy. Int J Prev Med. 2013; 4-7[PubMed]
  • 13. Tolou-Ghamari Z, Zare M, Habibabadi JM, Najafi MR. A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012. J Res Med Sci. 2013; 18-5[PubMed]
  • 14. French JA, Faught E. Rational polytherapy. Epilepsia. 2009; 50: 63-8[DOI]
  • 15. Guberman A. Monotherapy or polytherapy for epilepsy? . Can J Neurol Sci. 1998; 25(4)-8
  • 16. Arroyo S, Perucca E. Translating monotherapy trials into clinical practice: a look into the abyss. Epilepsy Behav. 2003; 4(5): 457-63[DOI]
  • 17. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE Treatment Guidelines: Evidence-based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes. Epilepsia. 2006; 47(7): 1094-120[DOI]
  • 18. Macdonald RL, Kelly KM. Antiepileptic Drug Mechanisms of Action. Epilepsia. 1995; 36[DOI]
  • 19. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An Overview of the Preclinical Aspects of Topiramate: Pharmacology, Pharmacokinetics, and Mechanism of Action. Epilepsia. 2000; 41: 3-9[DOI]
  • 20. Luszczki JJ, Czuczwar M, Kis J, Krysa J, Pasztelan I, Swiader M, et al. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia. 2003; 44(8): 1003-13[PubMed]
  • 21. Contin M, Riva R, Albani F, Avoni P, Baruzzi A. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2002; 24(3): 332-7[PubMed]
  • 22. Jenner P, Pratt JA, Marsden CD. Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT. Adv Neurol. 1986; 43: 629-43[PubMed]
  • 23. Mallucci GR, Nowack A, Malarkey EB, Yao J, Bleckert A, Hill J, et al. Levetiracetam Reverses Synaptic Deficits Produced by Overexpression of SV2A. PLoS ONE. 2011; 6(12)[DOI]
  • 24. Sankar R. GABAA Receptor Physiology and Its Relationship to the Mechanism of Action of the 1,5-Benzodiazepine Clobazam. CNS Drugs. 2012; 26(3): 229-44[DOI]
  • 25. Tapalaga D, Suciu A, Schvartz M, Duca S. [The mechanism of action of phenobarbital on the metabolism of 131J-B.S.P. in cholestasis induced by ANIT in isolated and perfused rat liver (author's transl)]. Dtsch Z Verdau Stoffwechselkr. 1979; 39(5): 233-7[PubMed]
  • 26. Holder JL Jr, Wilfong AA. Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2011; 12(16): 2573-81[DOI][PubMed]
  • 27. Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs. 2009; 23(2): 121-37[DOI][PubMed]
  • 28. Onuma T. [Cognitive dysfunction and antiepileptic drugs]. Brain Nerve. 2011; 63(4): 379-83[PubMed]
  • 29. Semah F, Thomas P, Coulbaut S, Derambure P. Early add-on treatment vs alternative monotherapy in patients with partial epilepsy. Epileptic Disord. 2014; [DOI][PubMed]
  • 30. Fröscher W, Rösche J. Fortschr Neurol Psychiatr. Combination Ther epilepsy. 2013; 81(1): 9-20
  • 31. Witt J, Elger CE, Helmstaedter C. Which drug-induced side effects would be tolerated in the prospect of seizure control? Epilepsy Behav. 2013; 29(1): 141-3[DOI]
  • 32. Poduri A, Sheidley BR, Shostak S, Ottman R. Genetic testing in the epilepsies—developments and dilemmas. Nat Rev Neurol. 2014; 10(5): 293-9[DOI]
  • 33. French JA, Gazzola DM. Antiepileptic drug treatment: new drugs and new strategies. Continuum (Minneap Minn). 2013; 19(3 Epilepsy): 643-55[DOI][PubMed]
  • 34. Yi Y, Lee JH, Suh ES. Toxic epidermal necrolysis induced by lamotrigine treatment in a child. Korean J Pedi. 2014; 57(3): 153[DOI]
  • 35. Sarangi SC, Tripathi M, Kakkar AK, Gupta YK. Effect of antiepileptic therapy on trace elements status in Indian population in a tertiary care hospital from northern India: A cross sectional study. Epilepsy Res. 2014; 108(5): 917-27[DOI][PubMed]
  • 36. Li M, Tan J, Yang X, Su L, Xie J, Liang B, et al. The ABCB1-C3435T polymorphism likely acts as a risk factor for resistance to antiepileptic drugs. Epilepsy Res. 2014; [DOI][PubMed]
  • 37. Satishchandra P, Santhosh N, Sinha S. Epilepsy: Indian perspective. Ann Indian Acad Neurol. 2014; 17(5): 3[DOI]
  • 38. Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013; 46(15): 1323-38[DOI][PubMed]
  • 39. Pegg EJ, Zaman F. Sodium valproate-related hyperammonaemic encephalopathy. Case Rep. 2014; 2014[DOI]
  • 40. Anwar MJ, Radhakrishna KV, Vohora D. Phenytoin and sodium valproate but not levetiracetam induce bone alterations in female mice. Can J Physiol Pharmacol. 2014; [DOI][PubMed]
  • 41. Shingade PU, Wankhede V, Kataria PS, Sonone N. Rare case of phenytoin induced acute generalized exanthematous pustulosis with cerebellar syndrome. Indian J Dermatol. 2014; 59(2): 210[DOI][PubMed]
  • 42. Błaszczyk B, Szpringer M, Czuczwar SJ, Lasoń W. Single centre 20 year survey of antiepileptic drug-induced hypersensitivity reactions. Pharmacoll Rep. 2013; 65(2): 399-409[DOI]
  • 43. Bourgeois BF. Initiating antiepileptic drug treatment and characteristics of drugs. Handb Clin Neurol. 2013; 111: 719-25[DOI][PubMed]
  • 44. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005; 352(21): 2211-21[DOI][PubMed]
  • 45. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother. 1995; 29(6): 619-24[PubMed]
  • 46. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003; 348(6): 529-37[DOI][PubMed]
  • 47. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001; 286(18): 2270-9[PubMed]
  • 48. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002; 3(2): 229-43[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments